Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4970970 | 1.00 | CA2 (0.68) | CA2LMNAALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL7346088 | 1.00 | CA2 (0.68) | CA2LMNAALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL8424531 | 0.89 | CA2 (0.54) | CA2LMNAALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL5968789 | 0.88 | CA2 (0.52) | CA2LMNAALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL13230301 | 0.87 | CA2 (0.51) | CA2LMNAALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL1136635 | 0.85 | CA2 (0.50) | CA2ALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL4295393 | 0.85 | CA2 (0.50) | CA2ALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL1136638 | 0.85 | CA2 (0.50) | CA2ALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL1018563 | 0.84 | CA2 (0.48) | CA2ALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL4823723 | 0.84 | CA2 (0.75) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | KANEKA CORPORATION (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1445324-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMAN DERIVATIVE AND INTERMEDIATE | KANEKA CORPORATION (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-6716998-B2 | SUCH AS (2R)-3,4-DIHYDRO-2H-CHROMEN-2-YL-METHYL-4-METHYL-BENZENESULFONATE; METATHESIS RING CLOSING POLYMERIZATION | WYETH | 2004-04-06 | — | — | US | disclosed |
| US-6667322-B2 | Useful for treatment of diseases such as obsessive compulsive disorder, panic attacks, anxiety, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-12-23 | — | — | US | disclosed |
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | WYETH | 2003-05-29 | — | — | US | disclosed |
| US-20030100774-A1 | Process for synthesis of 2-yl chroman derivatives | WYETH (US) | 2003-05-29 | — | — | US | disclosed |
| WO-2003031439-A1 | ANTIDEPRESSANT CHROMAN AND CHROMENE DERIVATIVES OF 3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE | WYETH (US) | 2003-04-17 | — | — | WO | disclosed |
| US-6060482-A | SEROTONIN INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-09 | — | — | US | disclosed |
| EP-0539803-B1 | Triazospirodecanone-methyl-chromans for the treatment of central nervous system illnesses | BAYER AG (DE) | 1999-01-07 | — | — | EP | disclosed |
| US-5696137-A | TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5696136-A | TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5693653-A | ADMINISTERING AN ANTIDEPRESSANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| US-5545643-A | USEFUL FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-13 | — | — | US | disclosed |
| EP-0546389-B1 | Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1996-04-17 | — | — | EP | disclosed |
| EP-0546388-B1 | Azaheterocyclylmethyl-chromans as agents for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1996-03-27 | — | — | EP | disclosed |
| US-5371094-A | Azaheterocyclylmethyl-chromans for treating axiety | BAYER AKTIENGESELLSCHAFT (DE) | 1994-12-06 | — | — | US | disclosed |
| US-5326771-A | Piperidylmethyl-substituted chroman derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1994-07-05 | — | — | US | disclosed |
| EP-0546389-A1 | Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1993-06-16 | — | — | EP | disclosed |
| EP-0546388-A1 | Azaheterocyclylmethyl-chromans as agents for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1993-06-16 | — | — | EP | disclosed |
| EP-0539803-A1 | Triazospirodecanone-methyl-chromans for the treatment of central nervous system illnesses | BAYER AG (DE) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100774-A1 | Process for synthesis of 2-yl chroman derivatives | CDYL, CDY1; CDY1B, CDYL2 | CA2 1314/4885LMNA 1602/4885ALDH1A1 1990/4885 |
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | CYP8B1, CYP3A43, HPD | CA2 825/4885LMNA 464/4885ALDH1A1 350/4885 |
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | TPH1, HTR1D, HTR1A | CA2 4518/4885LMNA 3052/4885ALDH1A1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.